Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo

BioMetals

Volumn 13, Issue 3, 2000, Pages 203-208

  Xing, Bengang ^a   Zhu, Huifang ^a   Wang, Yu ^b   Tang, Wenxia ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

JM216; Metallothionein; Oral administration; Oxidation state

Indexed keywords

ANTINEOPLASTIC AGENT; COPPER; METALLOTHIONEIN; PLATINUM; SATRAPLATIN; ZINC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; IN VIVO STUDY; KIDNEY; LIVER; MALE; NONHUMAN; PROTEIN SYNTHESIS; RABBIT; ROENTGEN SPECTROSCOPY; STOICHIOMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; INJECTIONS, SUBCUTANEOUS; INTUBATION, GASTROINTESTINAL; KIDNEY; LIVER; MALE; METALLOTHIONEIN; NITRATES; ORGAN SPECIFICITY; ORGANOPLATINUM COMPOUNDS; OXIDATION-REDUCTION; PLATINUM; RABBITS; ZINC COMPOUNDS;

EID: 0033724648     PISSN: 09660844     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009236927190     Document Type: Article

References (24)

1. 2DNA
2. Platinum(II) binding to metallothionein
3. Metallothioneins and their role in the metabolism and toxicity of metals
4. Gram scale purification and preparation of rabbit liver metallothionein
5. Carboxylation of kinetically inert platinum (IV) hydroxy complexes. An entree into orally active platinum (IV) antitumor agents
6. Spectroscopy properties of the cobalt(II) substituted-fragment of rabbit liver metallothionein
7. The reduction of Pt(IV) to Pt(II) by X-Ray and argon ion bombardment; evidence from X-Ray photoelectron spectrosopty
8. Preclinical antitumor evaluation of bis-acetato-ammine-dichlorocyclohexylamine (IV): An orally active platinum drug
9. Cisplatin
10. Phase I and pharmacological study of an oral platinum complex (JM216): Dose dependent pharmacokinatic with single dose administration
11. Phase I and pharmacokinatic study of an oral platinum complex given daily for 5 days in patients with cancer
12. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum (II) by induction of metallothionein synthesis without compromising its antitumor activity in mice
13. Long-term survival in ovarian cancer
14. Distinct metal-binding configurations in metallothionein
15. Ovarian cancer: New clinical approaches
16. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products
17. Biotransformation of the platinum drug JM216 following oral administration to cancer patients
18. cis-Platinum: Subcellular distribution and binding to cytosolic ligands
19. Induction of metallothionein synthesis by zinc in cadmium pretreated rats
20. Crystal and molecular structures of asymmetric cis- and trans-platinum (II/IV) compounds and their reactions with DNA fragments
21. Current status of platinum-based antitumor drugs
22. 6 with Metallothionein in vivo